Here, we confirmed for the first time that miR-338-3p targeting THBS1 reduced the levels of p-PI3K and p-Akt in glioma cells, indicating that miR-338-3p targeting THBS1 inhibited the activation of the PI3K/Akt pathway in glioma. Here, AKT1 is linked to central nervous system cancer.